Oculis Holding AG
OCS
Rank in Stocks
#12309
Oculis Holding AG is a biopharmaceutical company in the clinical development... Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Share Price
$7.76
Last synced: 2026-11-09
Market Cap
$479.04M
Change (1 day)
3.60%
Change (1 year)
-60.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oculis Holding AG (OCS)
Category
Healthcare
EPS for Oculis Holding AG (OCS)
EPS as of September 2026 TTM: $-1.67
According to Oculis Holding AG's latest financial reports, its current EPS (TTM) is $-1.67. At the end of 2025 the company had an EPS of $-2.28, an increase over its 2024 EPS of $-2.35.
EPS history for Oculis Holding AG from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.67 | -26.93% |
| 2025 | $-2.28 | -2.82% |
| 2024 | $-2.35 | -33.54% |
| 2023 | $-3.53 | 176.70% |
| 2022 | $-1.28 | 104.14% |
| 2021 | $-0.63 | 24.82% |
| 2020 | $-0.50 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,040.03% |
US
|
|
| $-7.07 | 324.40% |
US
|
|
| $-5.29 | 217.55% |
AU
|
|
| $12.88 | -873.16% |
BE
|
|
| $21.56 | -1,394.20% |
NL
|
Questions about Oculis Holding AG's earnings per share (EPS)
What is Oculis Holding AG's earnings per share (EPS)?
Oculis Holding AG's earnings per share (EPS) over the last twelve months is $-1.67, as of Sep 2026.
What was Oculis Holding AG's earnings per share (EPS) in 2025?
In 2025, Oculis Holding AG's earnings per share (EPS) was $-2.28, compared with $-2.35 in 2024.
How has Oculis Holding AG's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Oculis Holding AG's earnings per share (EPS) was highest in 2020 ($-0.50) and lowest in 2023 ($-3.53).
How does Oculis Holding AG's earnings per share (EPS) compare with similar companies?
Oculis Holding AG's earnings per share (EPS) ($-1.67) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.